In line with previous studies, we demonstrated that elevated liver enzyme levels were closely linked to poorer outcomes in patients with NAFLD, suggesting that GOT and GPT levels with demographic and clinical factors serve as strong prognostic biomarkers. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.